A research study published in the American Journal of Psychiatry showed Cannabidiol (CBD) to have positive effects on patients suffering from Schizophrenia. In a double blind study, patients were given either a placebo or 1g/day of CBD and assessed before and after treatment using several standard methodologies and metrics for evaluating mental health. The patients that supplemented treatment with CBD were less likely to experience psychotic symptoms as well as being less likely to be evaluated as ‘severely unwell.’

Additional improvements that fell short of statistical significance were also seen in general cognitive performance for the CBD group. The rates of adverse events in both groups were similar, therefore CBD was deemed to be well tolerated.